Justification of 150mg clopidogrel in patients with high on-clopidogrel platelet reactivity

European Journal of Clinical Investigation

Volumn 42, Issue 4, 2012, Pages 384-392

  Aradi, Dániel ^a   Rideg, Orsolya ^a   Vorobcsuk, András ^a   Magyarlaki, Tamás ^a   Magyari, Balázs ^a   Kónyi, Attila ^a   Pintér, Tünde ^a   Horváth, Iván G ^a   Komócsi, András ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Clopidogrel; High platelet reactivity; Outcome; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; DRUG DERIVATIVE; PHOSPHOPROTEIN; TICLOPIDINE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HIGH ON CLOPIDOGREL PLATELET REACTIVITY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SELF REPORT; STABLE ANGINA PECTORIS; THROMBOCYTE AGGREGATION; THROMBOCYTE DISORDER; TREATMENT DURATION; VASODILATATION; AGED; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; KAPLAN MEIER METHOD; MIDDLE AGED; STROKE; THROMBOCYTE; THROMBOSIS; TIME;

AGED; ANGINA, STABLE; BLOOD PLATELETS; CELL ADHESION MOLECULES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; STROKE; THROMBOSIS; TICLOPIDINE; TIME FACTORS;

EID: 84858280313     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02594.x     Document Type: Article

References (26)

1. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C et al. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
2. Rideg O, Komócsi A, Magyarlaki T, Tokés-Füzesi M, Miseta A, Kovács GL et al. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics 2011;Aug 1. [Epub ahead of print].
3. Aradi D, Rideg O, Komócsi A. Platelet function monitoring in patients on clopidogrel. Interv Med Appl Sci 2011;3:32-8.
4. Aradi D, Komócsi A, Vorobcsuk A, Rideg O, Tokés-Füzesi M, Magyarlaki T et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010;160:543-51.
5. Gurbel PA, Tantry US. Acceptance of high platelet reactivity as a risk factor: now, what do we do about it? JACC Cardiovasc Interv 2010;3:1008-10.
6. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2501-55.
7. von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75mg of clopidogrel for 30days. Eur Heart J 2007;28:1814-9.
8. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115:708-16.
9. Trenk D, Hochholzer W, Müller B, Stratz C, Valina CM, Schmiebusch P et al. Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement. EuroIntervention 2008;4:214-21.
10. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.
11. Ari H, Ozkan H, Karacinar A, Ari S, Koca V, Bozat T. The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (The EFFICIENT Trial). Int J Cardiol 2011;Epub ahead of print (Jan 14).
12. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-56.
13. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-50.
14. Aradi D, Kónyi A, Pálinkás L, Berki T, Pintér T, Tahin T et al. Thienopyridine therapy influences late outcome after coronary stent implantation. Angiology 2008;59:172-8.
15. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33.
16. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46.
17. Aradi D, Vorobcsuk A, Lenkey Z, Horváth IG, Komócsi A. Low platelet disaggregation predicts poor response to 150mg clopidogrel in patients with elevated platelet reactivity. Platelets 2010;21:1-10.
18. Pena A, Collet JP, Hulot JS, Silvain J, Barthélémy O, Beygui F et al. Can we override clopidogrel resistance? Circulation 2009;119:2854-7.
19. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010;121:1188-99.
20. Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011;4:403-10.
21. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
22. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schömig A et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690-7.
23. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-62.
24. The CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-42.
25. Patti G, Grieco D, Dicuonzo G, Pasceri V, Nusca A, Di Sciascio G. High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. J Am Coll Cardiol 2011;57:771-8.
26. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 2005;150:344-50.